Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
EONIS-Q Assay methodology, as part of the delivery and implementation of the ongoing NHS Newborn Blood Spot in-service evaluation (ISE) for Severe Combined Immuno-Deficiency (SCID) in 4 Screening laboratories, with the addition of the ISE for Spinal Muscular Atrophy (SMA).
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Revvity (UK) Limited | 03763278 | £4,074,117 | - |
Government spending data: This supplier has received £244,996,091 in 332 payments (over £25k) from Department of Health and Social Care, UK Health Security Agency, NHS England, Manchester University NHS Foundation Trust, East Sussex Healthcare NHS Trust and 7 more public bodies (2016-04-01 to 2026-05-20). View full payment history →